Search Results
Mar 18, 2026, 08:30 ET Commvault Expands Threat Scan with Layered Threat Detection to Advance Verified Clean Recoveries
https://www.verizon.com/business/resources/T16f/reports/2025-dbir-data-breach-investigations-report.pdf
More news about: COMMVAULT
Mar 18, 2026, 08:15 ET HBCUs Compete for Over $500,000 and National Championship Title at 37th Honda Campus All-Star Challenge
CollegeMississippi Valley State UniversityMorehouse CollegeNorfolk State UniversityNorth Carolina A&T State UniversityNorth Carolina Central UniversityOakwood UniversityPaul Quinn CollegePrairie
More news about: American Honda Motor Co., Inc.
Mar 18, 2026, 08:01 ET Banks Strengthen Mobile Account Opening and Debit Card Controls While Delegated Access Emerges for Retail Customers to Safeguard Vulnerable Populations
encompasses the mobile apps and websites of Bank of America, BMO, Capital One, Chase, Citibank, Citizens Bank, Fifth Third Bank, Huntington Bank, KeyBank, M&T Bank, PNC, Regions Bank, TD Bank, Truist, USAA, U.S. Bank, and Wells Fargo. A separate semi-annual Online Banker Scorecard reviews the online banking
More news about: Keynova Group
Mar 18, 2026, 08:00 ET Mammotome Secures FDA Clearance for Industry-First, In‑Room MR Vacuum‑Assisted Breast Biopsy System and New HydroMARK™ Plus MR Biopsy Site Markers
cavity 6. The HydroMARK™ Plus marker incorporates the exclusive hydrogel technology and titanium shapes that provide visibility under both T1 and T2 MRI sequences without excessive bloom5. In addition, the marker is designed to attach to tissue upon deployment and features "wings" designed
More news about: MAMMOTOME
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
PsO.2,23,24 ICOTYDE binds to the IL-23 receptor with high affinity and demonstrated potent, inhibition of IL-23 signaling in human T cells.25 Clinical significance of these findings is unknown.ICOTYDE is currently approved in the U.S. for the treatment of adults, and
More news about: Johnson & Johnson
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
domain-specific binding and downstream effects on key cellular signaling pathways, with insights into activity in models following trastuzumab deruxtecan (T-DXd) exposure.A poster presentation featuring preclinical data supporting the activity of JZP898 – currently in Phase 1 development – including
More news about: Jazz Pharmaceuticals plc
Mar 18, 2026, 07:01 ET Kali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis
dosing is underway for the first cohort of patients in its Phase 1a clinical trial evaluating KT501. KT501 is a first-in-class CD19xBCMAxCD3 trispecific T-cell engager (TCE). The study is being conducted in adult patients with Rheumatoid Arthritis (RA).
More news about: Kali Therapeutics
Mar 18, 2026, 07:00 ET AT&T Launches New App to Simplify Customers' Digital Experience
more features to come throughout the year.The News:Beginning today, AT&T is starting to roll out the new AT&T app, a simpler way to experience all of AT&T in one convenient place. The app makes it easier to manage all services, and it provides a one-stop
More news about: AT&T
Mar 18, 2026, 07:00 ET GentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes
EngTreg investigational therapy for adults recently diagnosed with type 1 diabetes (T1D). GNTI-122 is designed to reduce or eliminate the need for life-long insulin injections in patients recently diagnosed with T1D."Dosing the first participant in the POLARIS trial is an important milestone for
More news about: GentiBio, Inc.
Mar 18, 2026, 07:00 ET Summit Nanotech Brings Digital Twin Capability to Commercial DLE Design
decisions made during brine validation to flow directly into commercial plant engineering.Summit's denaLi™ DLE technology has achieved a projected ~$1,000/t LCE reduction in project lifecycle costs compared to leading competitor benchmarks. The Predictive Modeling Platform contributes directly to that
More news about: Summit Nanotech
Mar 18, 2026, 07:00 ET BOARDWALKTECH SIGNS NEW CONTRACT WITH SEMICONDUCTOR COMPANY
of the data entering most organizations remains unstructured, existing in the form of documents, emails, workflows, and communications," said Andrew T. Duncan, CEO of Boardwalktech. "The Boardwalk Unity Central platform seamlessly connects these documents, messages, files, workflows, and alerts into
More news about: Boardwalktech Software Corp.
Mar 18, 2026, 07:00 ET Summit Nanotech incorpora capacidad de gemelo digital al diseño comercial de DLE
incorporen directamente en la ingeniería de la planta comercial.La tecnología DLE denaLi™ de Summit ha logrado una reducción proyectada de ~US$1.000/t LCE en costos del ciclo de vida del proyecto en comparación con los benchmarks de los principales competidores. La Plataforma de Modelamiento Predictivo
More news about: Summit Nanotech
Mar 18, 2026, 06:56 ET Former Canadian Prime Minister Rt. Hon. Justin Trudeau to Headline EuroFinance International 2026
https://we.tl/t-sfj7qgbgmq Logo: https://mma.prnewswire.com/media/2936875/EuroFinance_Logo.jpg
More news about: EuroFinance, Part of Economist Impact
Mar 18, 2026, 06:00 ET CUJO AI First to Deliver Network-Level Protection Against Crypto Investment Scams
Fully compliant with all privacy regulations, CUJO AI is trusted by the world's largest broadband operators, including Comcast, Charter Communications, T-Mobile USA, Deutsche Telekom, TELUS, Sky Italia, Sky UK, Rogers, Cox, Shaw, Videotron, BT and EE.CONTACT: Viktorija Vilke
More news about: CUJO AI
Mar 18, 2026, 05:00 ET Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
capable of designing diverse therapeutics directly from a disease prompt. In wet-lab validation, EDEN demonstrated zero-shot activity in primary human T-cells without any human or clinical data needed. The model has successfully generated hits across multiple frontier modalities, notably pioneering AI-Programmable
More news about: Basecamp Research
Mar 18, 2026, 05:00 ET Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
capable of designing diverse therapeutics directly from a disease prompt. In wet-lab validation, EDEN demonstrated zero-shot activity in primary human T-cells without any human or clinical data needed. The model has successfully generated hits across multiple frontier modalities, notably pioneering AI-Programmable
More news about: Basecamp Research
Mar 18, 2026, 04:00 ET NeoNephos Foundation Welcomes BWI GmbH, SUSE LLC, and Fraunhofer ISST as Members
way to accelerate innovation for the EU open source community."The NeoNephos member community includes organizations such as SAP SE, STACKIT, T‑Systems International GmbH, x‑cellent technologies GmbH, Cyberus Technology, Liquid Reply, Nearby Computing, ape factory, TNO (Netherlands Organisation
More news about: Linux Foundation Europe
Mar 18, 2026, 03:01 ET Change in trading currency of Compass Group's Ordinary Shares
Legal Entity Identifier (LEI) No. 2138008M6MH9OZ6U2T68LONDON, March 18, 2026 /PRNewswire/ --
More news about: Compass Group
Mar 17, 2026, 21:30 ET Elliott Management Statement on Mitsui O.S.K. Lines, Ltd.
Advisors (UK) LimitedT: +44 20 3009 [email protected] YorkStephen SpruiellElliott Investment Management L.P.T: +1 (212) 478-2017
More news about: Elliott Investment Management L.P.
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
ATG-106, a novel "2+1"format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacyAbstract Number: 1621Session Category: ImmunologySession Title: T Cell Engagers 1Date: April
More news about: Antengene Corporation Limited
Mar 17, 2026, 19:00 ET Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 - at AACR Annual Meeting 2026
require additional co-stimulation. KIR-CAR enables sustained chimeric receptor expression with improved long-term CAR T cell function and decreased T cell exhaustion. This results in CAR T cell resistance to tumor immunosuppression, prolonged functional persistence and improved tumor elimination. Together,
More news about: Verismo Therapeutics
Mar 17, 2026, 17:41 ET /C O R R E C T I O N -- OnPoint Community Credit Union/
More news about: OnPoint Community Credit Union
Mar 17, 2026, 17:00 ET GV20 Therapeutics Announces Late-Breaking Oral Presentation of GV20-0251 Translational Findings at the AACR Annual Meeting 2026
Li et al, Cell 2024). Preclinical studies show that anti-IGSF8 antibodies enhance NK cell cytotoxicity, dendritic cell antigen presentation, and T cell activation, both alone and with anti-PD1. GV20-0251 advanced from target discovery to IND in three years, marking a paradigm shift in AI-driven antibody
More news about: GV20 Therapeutics
Mar 17, 2026, 16:19 ET Sequential™ lève 3,5 millions de dollars pour construire une plateforme de découverte alimentée par l'IA pour les tests multi-omiques et les ingrédients de nouvelle génération pour la santé de la peau
des laboratoires à Cambridge, New York City et Singapour. La société a reçu le titre de solution de test « la plus importante » de l'industrie - (C&T, 2022). À ce jour, Sequential a recueilli plus de 50 000 échantillons de microbiome cutané humain et les formulations correspondantes ont été testées
More news about: Sequential
Mar 17, 2026, 16:01 ET Health In Tech and Amazon Web Service Advanced Tier Service Partner Ciklum Announce Strategic Collaboration to Accelerate Development of AI-Driven InsurTech Platform
[email protected] Equity GroupKalle Ahl, CFA T: (303) [email protected] Sullivan,
More news about: Health In Tech Inc.